Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial

Abdulhamied Alfaddagh, Tarec K Elajami, Hasan Ashfaque, Mohamad Saleh, Bruce R Bistrian, Francine K Welty, Abdulhamied Alfaddagh, Tarec K Elajami, Hasan Ashfaque, Mohamad Saleh, Bruce R Bistrian, Francine K Welty

Abstract

Background: Although statins reduce cardiovascular events, residual risk remains. Therefore, additional modalities are needed to reduce risk. We evaluated the effect of eicosapentaenoic acid and docosahexaenoic acid in pharmacologic doses added to statin treatment on coronary artery plaque volume.

Methods and results: A total of 285 subjects with stable coronary artery disease on statins were randomized to omega-3 ethyl-ester (1.86 g of eicosapentaenoic acid and 1.5 g of docosahexaenoic acid daily) or no omega-3 (control) for 30 months. Coronary plaque volume was assessed by coronary computed tomographic angiography. Mean (SD) age was 63.0 (7.7) years; mean low-density lipoprotein cholesterol ≤80 mg/dL. In the intention-to-treat analysis, our primary endpoint, noncalcified plaque volume, was not different between groups (P=0.14) but approached significance in the per protocol analysis (P=0.07). When stratified by age in the intention-to-treat analysis, younger omega-3 subjects had significantly less progression of the primary endpoint, noncalcified plaque (P=0.013), and fibrous, calcified and total plaque. In plaque subtype analysis, controls had significant progression of fibrous plaque compared to no change in the omega-3 ethyl-ester group (median % change [interquartile range], 5.0% [-5.7, 20.0] versus -0.1% [-12.3, 14.5], respectively; P=0.018). Among those on low-intensity statins, omega-3 ethyl-ester subjects had attenuation of fibrous plaque progression compared to controls (median % change [interquartile range], 0.3% [-12.8, 9.0] versus 4.8% [-5.1, 19.0], respectively; P=0.032). In contrast, those on high-intensity statins had no difference in plaque change in either treatment arm.

Conclusions: High-dose eicosapentaenoic acid and docosahexaenoic acid provided additional benefit to statins in preventing progression of fibrous coronary plaque in subjects adherent to therapy with well-controlled low-density lipoprotein cholesterol levels. The benefit on low-intensity statin, but not high-intensity statin, suggests that statin intensity affects plaque volume.

Clinical trial registration: URL: http://www.ClinicalTrials.gov. Unique identifier: NCT01624727.

Keywords: coronary computed tomography angiography; coronary plaque subtype; eicosapentaenoic acid; omega‐3 fatty acids; plaque progression.

© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

Figures

Figure 1
Figure 1
Consolidated standards of reporting trials diagram. CCTA indicates coronary computed tomographic angiography.

References

    1. Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14:1–10.
    1. Bayturan O, Kapadia S, Nicholls SJ, Tuzcu EM, Shao M, Uno K, Shreevatsa A, Lavoie AJ, Wolski K, Schoenhagen P, Nissen SE. Clinical predictors of plaque progression despite very low levels of low‐density lipoprotein cholesterol. J Am Coll Cardiol. 2010;55:2736–2742.
    1. Nicholls SJ, Hsu A, Wolski K, Hu B, Bayturan O, Lavoie A, Uno K, Tuzcu EM, Nissen SE. Intravascular ultrasound‐derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol. 2010;55:2399–2407.
    1. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators . Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open‐label, blinded endpoint analysis. Lancet. 2007;369:1090–1098.
    1. Obaid DR, Calvert PA, Gopalan D, Parker RA, West NE, Goddard M, Rudd JH, Bennett MR. Dual‐energy computed tomography imaging to determine atherosclerotic plaque composition: a prospective study with tissue validation. J Cardiovasc Comput Tomogr. 2014;8:230–237.
    1. Obaid DR, Calvert PA, Gopalan D, Parker RA, Hoole SP, West NE, Goddard M, Rudd JH, Bennett MR. Atherosclerotic plaque composition and classification identified by coronary computed tomography: assessment of computed tomography‐generated plaque maps compared with virtual histology intravascular ultrasound and histology. Circ Cardiovasc Imaging. 2013;6:655–664.
    1. Rinehart S, Vazquez G, Qian Z, Murrieta L, Christian K, Voros S. Quantitative measurements of coronary arterial stenosis, plaque geometry, and composition are highly reproducible with a standardized coronary arterial computed tomographic approach in high‐quality CT datasets. J Cardiovasc Comput Tomogr. 2011;5:35–43.
    1. Sandfort V, Lima JA, Bluemke DA. Noninvasive imaging of atherosclerotic plaque progression: status of coronary computed tomography angiography. Circ Cardiovasc Imaging. 2015;8:e003316.
    1. Burgstahler C, Reimann A, Beck T, Kuettner A, Baumann D, Heuschmid M, Brodoefel H, Claussen CD, Kopp AF, Schroeder S. Influence of a lipid‐lowering therapy on calcified and noncalcified coronary plaques monitored by multislice detector computed tomography: results of the New Age II Pilot Study. Invest Radiol. 2007;42:189–195.
    1. Hoffmann H, Frieler K, Schlattmann P, Hamm B, Dewey M. Influence of statin treatment on coronary atherosclerosis visualised using multidetector computed tomography. Eur Radiol. 2010;20:2824–2833.
    1. Inoue K, Motoyama S, Sarai M, Sato T, Harigaya H, Hara T, Sanda Y, Anno H, Kondo T, Wong ND, Narula J, Ozaki Y. Serial coronary CT angiography‐verified changes in plaque characteristics as an end point: evaluation of effect of statin intervention. JACC Cardiovasc Imaging. 2010;3:691–698.
    1. Shimojima M, Kawashiri MA, Nitta Y, Yoshida T, Katsuda S, Kaku B, Taguchi T, Hasegawa A, Konno T, Hayashi K, Yamagishi M. Rapid changes in plaque composition and morphology after intensive lipid lowering therapy: study with serial coronary CT angiography. Am J Cardiovasc Dis. 2012;2:84–88.
    1. Zeb I, Li D, Nasir K, Malpeso J, Batool A, Flores F, Dailing C, Karlsberg RP, Budoff M. Effect of statin treatment on coronary plaque progression—a serial coronary CT angiography study. Atherosclerosis. 2013;231:198–204.
    1. Khosa F, Khan AN, Nasir K, Bedayat A, Malik Z, Jon AF, Cheema AR, Clouse ME, Welty FK. Comparison of coronary plaque subtypes in male and female patients using 320‐row MDCTA. Atherosclerosis. 2013;226:428–432.
    1. Hauser TH, Salastekar N, Schaefer EJ, Desai T, Goldfine HL, Fowler KM, Weber GM, Welty F, Clouse M, Shoelson SE, Goldfine AB; Targeting Inflammation Using Salsalate in Cardiovascular Disease (TINSAL‐CVD) Study Team . Effect of targeting inflammation with salsalate: the TINSAL‐CVD randomized clinical trial on progression of coronary plaque in overweight and obese patients using statins. JAMA Cardiol. 2016;1:413–423.
    1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645.
    1. Dietary supplementation with n‐3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI‐Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354:447–455.
    1. GISSI‐HF Investigators . Effect of n‐3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI‐HF trial): a randomised, double‐blind, placebo controlled trial. Lancet. 2008;372:1223–1230.
    1. de Lorgeril M, Salen P, Defaye P, Rabaeus M. Recent findings on the health effects of omega‐3 fatty acids and statins, and their interactions: do statins inhibit omega‐3? BMC Med. 2013;11:5.
    1. Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, Gottwik M, Steinbeck G, Del Castillo U, Sack R, Worth H, Katus H, Spitzer W, Sabin G, Senges J; OMEGA Study Group . OMEGA, a randomized, placebo‐controlled trial to test the effect of highly purified omega‐3 fatty acids on top of modern guideline‐adjusted therapy after myocardial infarction. Circulation. 2010;22:2152–2159.
    1. Kromhout D, Giltay EJ, Gelejinse JM; Alpha Omega Trial Group . n‐3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363:2015–2026.
    1. Brodoefel H, Burgstahler C, Sabir A, Yam CS, Khosa F, Claussen CD, Clouse ME. Coronary plaque quantification by voxel analysis: dual‐source MDCT angiography versus intravascular sonography. AJR Am J Roentgenol. 2009;192:W84–W89.
    1. Voros S, Rinehart S, Qian Z, Joshi P, Vazquez G, Fischer C, Belur P, Hulten E, Villines TC. Coronary atherosclerosis imaging by coronary CT angiography: current status, correlation with intravascular interrogation and meta‐analysis. JACC Cardiovasc Imaging. 2011;4:537–548.
    1. Brodoefel H, Burgstahler C, Heuschmid M, Reimann A, Khosa F, Kopp A, Schroeder S, Claussen CD, Clouse ME. Accuracy of dual‐source CT in the characterisation of non‐calcified plaque: use of a colour‐coded analysis compared with virtual histology intravascular ultrasound. Br J Radiol. 2009;82:805–812.
    1. Eussen SR, Geleijnse JM, Giltay EJ, Rompelberg CJ, Klungel OH, Kromhout D. Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. Eur Heart J. 2012;33:1582–1588.
    1. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626–635.
    1. Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res. 2014;114:1867–1879.
    1. Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242:357–366.
    1. Budoff M. Triglycerides and triglyceride‐rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016;118:138–145.
    1. Gdula‐Argasińska J, Czepiel J, Woźniakiewicz A, Wojtoń K, Grzywacz A, Woźniakiewicz M, Jurczyszyn A, Perucki W, Librowski T. n‐3 Fatty acids as resolvents of inflammation in the A549 cells. Pharmacol Rep. 2015;67:610–615.
    1. Nelson JR, Wani O, May HT, Budoff M. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. Vascul Pharmacol. 2017;91:1–9.
    1. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti‐inflammatory and pro‐resolution lipid mediators. Nat Rev Immunol. 2008;8:349–361.
    1. Serhan CN. Pro‐resolving lipid mediators are leads for resolution physiology. Nature. 2014;510:92–101.
    1. Tabas I, Glass CK. Anti‐inflammatory therapy in chronic disease: challenges and opportunities. Science. 2013;339:166–172.
    1. Heydari B, Abdullah S, Pottala JV, Shah R, Abbasi S, Mandry D, Francis SA, Lumish H, Ghoshhajra BB, Hoffman U, Appelbaum E, Feng JH, Blankstein R, Steigner M, McConnell JP, Harris W, Antman EM, Jerosch‐Herold M, Kwong RY. Effect of omega‐3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: the OMEGA‐REMODEL Randomized Clinical Trial. Circulation. 2016;134:378–391.
    1. Barden A, Mas E, Croft KD, Phillips M, Mori TA. Short‐term n‐3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation. J Lipid Res. 2014;55:2401–2407.
    1. Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN. Identification and signature profiles for pro‐resolving and inflammatory lipid mediators in human tissue. Am J Physiol Cell Physiol. 2014;307:C39–C54.
    1. Mas E, Croft KD, Zahra P, Barden A, Mori TA. Resolvins D1, D2, and other mediators of self‐limited resolution of inflammation in human blood following n‐3 fatty acid supplementation. Clin Chem. 2012;58:1476–1484.
    1. Elajami TK, Colas RA, Dalli J, Chiang N, Serhan CN, Welty FK. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J. 2016;30:2792–2801.
    1. Lee CR, Zeldin DC. Resolvin infectious inflammation by targeting the host response. N Engl J Med. 2015;373:2183–2185.
    1. Dalli J, Chiang N, Serhan CN. Elucidation of novel 13‐series resolvins that increase with atorvastatin and clear infections. Nat Med. 2015;21:1071–1075.
    1. Mita T, Watada H, Ogihara T, Nomiyama T, Ogawa O, Kinoshita J, Shimizu T, Hirose T, Tanaka Y, Kawamori R. Eicosapentaenoic acid reduces the progression of carotid intima‐media thickness in patients with type 2 diabetes. Atherosclerosis. 2007;191:162–167.
    1. Erkkilä AT, Matthan NR, Herrington DM, Lichtenstein AH. Higher plasma docosahexaenoic acid is associated with reduced progression of coronary atherosclerosis in women with CAD. J Lipid Res. 2006;47:2814–2819.
    1. Watanabe T, Ando K, Daidoji H, Otaki Y, Sugawara S, Matsui M, Ikeno E, Hirono O, Miyawaki H, Yashiro Y, Nishiyama S, Arimoto T, Takahashi H, Shishido T, Miyashita T, Miyamoto T, Kubota I; CHERRY study investigators . A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol. 2017;70:537–544.
    1. Niki T, Wakatsuki T, Yamaguchi K, Taketani Y, Oeduka H, Kusunose K, Ise T, Iwase T, Yamada H, Soeki T, Sata M. Effects of the addition of eicosapentaenoic acid to strong statin therapy on inflammatory cytokines and coronary plaque components assessed by integrated backscatter intravascular ultrasound. Circ J. 2016;80:450–460.
    1. Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, Kunishima T, Sato A, Nozato T, Miyake S, Takeyama Y, Morino Y, Yamauchi T, Muramatsu T, Hibi K, Terashima M, Michishita I. Low serum docosahexaenoic acid is associated with progression of coronary atherosclerosis in statin‐treated patients with diabetes mellitus: results of the treatment with statin on atheroma regression evaluated by intravascular ultrasound with virtual histology (TRUTH) study. Cardiovasc Diabetol. 2014;13:13.
    1. Nadjiri J, Hausleiter J, Jähnichen C, Will A, Hendrich E, Martinoff S, Hadamitzky M. Incremental prognostic value of quantitative plaque assessment in coronary CT angiography during 5 years of follow up. J Cardiovasc Comput Tomogr. 2016;10:97–104.
    1. Versteylen MO, Kietselaer BL, Dagnelie PC, Joosen IA, Dedic A, Raaijmakers RH, Wildberger JE, Nieman K, Crijns HJ, Niessen WJ, Daemen MJ, Hofstra L. Additive value of semiautomated quantification of coronary artery disease using cardiac computed tomographic angiography to predict future acute coronary syndrome. J Am Coll Cardiol. 2013;61:2296–2305.
    1. Motoyama S, Sarai M, Harigaya H, Anno H, Inoue K, Hara T, Naruse H, Ishii J, Hishida H, Wong ND, Virmani R, Kondo T, Ozaki Y, Narula J. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol. 2009;54:49–57.
    1. Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low‐density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol. 2012;6:5–18.
    1. Wei MW, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta‐analysis. Curr Atheroscler Rep. 2011;13:474–483.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren